Ex vivo and in vivo gene transfer to the skin using replication-deficient recombinant adenovirus vectors

Yasuhiro Setoguchi, H. Ari Jaffe, Claire Danel, Ronald Crystal

Research output: Contribution to journalArticle

90 Citations (Scopus)

Abstract

The skin has the potential for a variety of gene therapy applications. In addition to local delivery, it is the largest organ of the body, and highly vascular, and thus is an ideal site for systemic delivery of gene products. To evaluate the potential for adenovirus-mediated skin gene transfer, the replicationdeficient recombinant adenovirus vectors Ad.RSVβgal (coding for Escherichia coli β-galactosidase) and Adα1AT (coding for human α1-antitrypsin) were used in both ex vivo and in vivo approaches. Following in vitro infection with Ad.RSVβgal, murine keratinocytes expressed β-galactosidase. Parallel in vitro studies with Adα1AT documented de novo synthesis and secretion of human α1AT as shown by [35s]methionine labeling and immunoprecipitation. Quantification of human α1AT in the culture supernatants demonstrated 0.1 - 0.3 μg human α1 AT secreted/ml-24 h. Evaluation of the serum of mice receiving transplants (105 cells/ mouse) of Adα1AT-infected syngeneic keratinocytes demonstrated human α1AT for at least 14 d with maximum levels of 41 ng/ml. To demonstrate the feasibility of direct adenovirus-mediated in vivo transfer of genes to the skin, Ad.RSVβgal or Adα1AT were administered subcutaneously to mice. Histologic evaluation after 4 demonstrated expression of β-galactosidase in various types of skin cells. Quantification of human α1 AT in serum of animals infected subcutaneously with Adα1AT showed levels of 53 ng/ml at day 4, with human α1AT detectable for at least 14 d. These observations support the feasibility of ex vivo and in vivo gene transfer to the skin mediated by replication-deficient adenovirus vectors.

Original languageEnglish
Pages (from-to)415-421
Number of pages7
JournalJournal of Investigative Dermatology
Volume102
Issue number4
DOIs
Publication statusPublished - 1 Jan 1994
Externally publishedYes

Fingerprint

Gene transfer
Adenoviridae
Galactosidases
Skin
Genes
Keratinocytes
Gene therapy
Transplants
Methionine
Labeling
Escherichia coli
Animals
Serum
Immunoprecipitation
Genetic Therapy
Blood Vessels
Infection

Keywords

  • Gene therapy
  • keratinocyte
  • α1-antitrypsin
  • β-galactosidase

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Dermatology
  • Cell Biology

Cite this

Ex vivo and in vivo gene transfer to the skin using replication-deficient recombinant adenovirus vectors. / Setoguchi, Yasuhiro; Jaffe, H. Ari; Danel, Claire; Crystal, Ronald.

In: Journal of Investigative Dermatology, Vol. 102, No. 4, 01.01.1994, p. 415-421.

Research output: Contribution to journalArticle

@article{d8d1d466b0944f9790d849fc4642a5a2,
title = "Ex vivo and in vivo gene transfer to the skin using replication-deficient recombinant adenovirus vectors",
abstract = "The skin has the potential for a variety of gene therapy applications. In addition to local delivery, it is the largest organ of the body, and highly vascular, and thus is an ideal site for systemic delivery of gene products. To evaluate the potential for adenovirus-mediated skin gene transfer, the replicationdeficient recombinant adenovirus vectors Ad.RSVβgal (coding for Escherichia coli β-galactosidase) and Adα1AT (coding for human α1-antitrypsin) were used in both ex vivo and in vivo approaches. Following in vitro infection with Ad.RSVβgal, murine keratinocytes expressed β-galactosidase. Parallel in vitro studies with Adα1AT documented de novo synthesis and secretion of human α1AT as shown by [35s]methionine labeling and immunoprecipitation. Quantification of human α1AT in the culture supernatants demonstrated 0.1 - 0.3 μg human α1 AT secreted/ml-24 h. Evaluation of the serum of mice receiving transplants (105 cells/ mouse) of Adα1AT-infected syngeneic keratinocytes demonstrated human α1AT for at least 14 d with maximum levels of 41 ng/ml. To demonstrate the feasibility of direct adenovirus-mediated in vivo transfer of genes to the skin, Ad.RSVβgal or Adα1AT were administered subcutaneously to mice. Histologic evaluation after 4 demonstrated expression of β-galactosidase in various types of skin cells. Quantification of human α1 AT in serum of animals infected subcutaneously with Adα1AT showed levels of 53 ng/ml at day 4, with human α1AT detectable for at least 14 d. These observations support the feasibility of ex vivo and in vivo gene transfer to the skin mediated by replication-deficient adenovirus vectors.",
keywords = "Gene therapy, keratinocyte, α1-antitrypsin, β-galactosidase",
author = "Yasuhiro Setoguchi and Jaffe, {H. Ari} and Claire Danel and Ronald Crystal",
year = "1994",
month = "1",
day = "1",
doi = "10.1111/1523-1747.ep12372181",
language = "English",
volume = "102",
pages = "415--421",
journal = "Journal of Investigative Dermatology",
issn = "0022-202X",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Ex vivo and in vivo gene transfer to the skin using replication-deficient recombinant adenovirus vectors

AU - Setoguchi, Yasuhiro

AU - Jaffe, H. Ari

AU - Danel, Claire

AU - Crystal, Ronald

PY - 1994/1/1

Y1 - 1994/1/1

N2 - The skin has the potential for a variety of gene therapy applications. In addition to local delivery, it is the largest organ of the body, and highly vascular, and thus is an ideal site for systemic delivery of gene products. To evaluate the potential for adenovirus-mediated skin gene transfer, the replicationdeficient recombinant adenovirus vectors Ad.RSVβgal (coding for Escherichia coli β-galactosidase) and Adα1AT (coding for human α1-antitrypsin) were used in both ex vivo and in vivo approaches. Following in vitro infection with Ad.RSVβgal, murine keratinocytes expressed β-galactosidase. Parallel in vitro studies with Adα1AT documented de novo synthesis and secretion of human α1AT as shown by [35s]methionine labeling and immunoprecipitation. Quantification of human α1AT in the culture supernatants demonstrated 0.1 - 0.3 μg human α1 AT secreted/ml-24 h. Evaluation of the serum of mice receiving transplants (105 cells/ mouse) of Adα1AT-infected syngeneic keratinocytes demonstrated human α1AT for at least 14 d with maximum levels of 41 ng/ml. To demonstrate the feasibility of direct adenovirus-mediated in vivo transfer of genes to the skin, Ad.RSVβgal or Adα1AT were administered subcutaneously to mice. Histologic evaluation after 4 demonstrated expression of β-galactosidase in various types of skin cells. Quantification of human α1 AT in serum of animals infected subcutaneously with Adα1AT showed levels of 53 ng/ml at day 4, with human α1AT detectable for at least 14 d. These observations support the feasibility of ex vivo and in vivo gene transfer to the skin mediated by replication-deficient adenovirus vectors.

AB - The skin has the potential for a variety of gene therapy applications. In addition to local delivery, it is the largest organ of the body, and highly vascular, and thus is an ideal site for systemic delivery of gene products. To evaluate the potential for adenovirus-mediated skin gene transfer, the replicationdeficient recombinant adenovirus vectors Ad.RSVβgal (coding for Escherichia coli β-galactosidase) and Adα1AT (coding for human α1-antitrypsin) were used in both ex vivo and in vivo approaches. Following in vitro infection with Ad.RSVβgal, murine keratinocytes expressed β-galactosidase. Parallel in vitro studies with Adα1AT documented de novo synthesis and secretion of human α1AT as shown by [35s]methionine labeling and immunoprecipitation. Quantification of human α1AT in the culture supernatants demonstrated 0.1 - 0.3 μg human α1 AT secreted/ml-24 h. Evaluation of the serum of mice receiving transplants (105 cells/ mouse) of Adα1AT-infected syngeneic keratinocytes demonstrated human α1AT for at least 14 d with maximum levels of 41 ng/ml. To demonstrate the feasibility of direct adenovirus-mediated in vivo transfer of genes to the skin, Ad.RSVβgal or Adα1AT were administered subcutaneously to mice. Histologic evaluation after 4 demonstrated expression of β-galactosidase in various types of skin cells. Quantification of human α1 AT in serum of animals infected subcutaneously with Adα1AT showed levels of 53 ng/ml at day 4, with human α1AT detectable for at least 14 d. These observations support the feasibility of ex vivo and in vivo gene transfer to the skin mediated by replication-deficient adenovirus vectors.

KW - Gene therapy

KW - keratinocyte

KW - α1-antitrypsin

KW - β-galactosidase

UR - http://www.scopus.com/inward/record.url?scp=0028281972&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028281972&partnerID=8YFLogxK

U2 - 10.1111/1523-1747.ep12372181

DO - 10.1111/1523-1747.ep12372181

M3 - Article

VL - 102

SP - 415

EP - 421

JO - Journal of Investigative Dermatology

JF - Journal of Investigative Dermatology

SN - 0022-202X

IS - 4

ER -